Showing results (351-360 of 494) with videos related to
Sort By:
Pageof 50
International Journal of Molecular Sciences|February 27, 2026
Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in ChondrosarcomaAgnieszka E Zając, Piotr Rutkowski, Anna Szumera-Ciećkiewicz, et al.European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 1, 2020
Quality of treatment and surgical approach for rectal gastrointestinal stromal tumour (GIST) in a large European cohortNikki S IJzerman, Mahmoud Mohammadi, Dimitri Tzanis, et al.Annals of Surgery|January 5, 2016
Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working GroupAlessandro Gronchi, Dirk C Strauss, Rosalba Miceli, et al.Immunotherapy|December 23, 2020
First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in PolandBożena Cybulska-Stopa, Renata Pacholczak-Madej, Grażyna Kamińska-Winciorek, et al.Journal of Cancer Research and Clinical Oncology|November 28, 2024
Comparing epidemiological and clinical data from RPS patients documented in a German cancer registry to a cohort from TARPSWG reference centresFranziska Neemann, Lina Jansen, Silke Hermann, et al.Cancer Research Communications|June 11, 2026
Predicting clinical sensitivities of PDGFRA exon 18 mutations to imatinib and avapritinib to optimize gastrointestinal stromal tumor treatmentHomma M Khosroyani, Alina Teuber, Ajia Town, et al.Future Oncology (London, England)|December 25, 2019
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanomaJason J Luke, Paolo A Ascierto, Matteo S Carlino, et al.Cancer|February 3, 2017
Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Trans-Atlantic RPS Working GroupAndrea J MacNeill, Rosalba Miceli, Dirk C Strauss, et al.The Lancet. Oncology|July 3, 2020
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trialMichael C Heinrich, Robin L Jones, Margaret von Mehren, et al.Lancet (London, England)|June 28, 2012
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Jean-Jacques Grob, Lev V Demidov, et al.Pageof 50